Posted by Michael Wonder on 07 Jul 2020
Use of infliximab biosimilar in Medicare population is low but growing
7 July 2020 - Slow growth of use of biosimilar infliximab in a Medicare fee-for-service population suggests lingering hesitancy on the part of gastro-enterologists and patients, particularly when it comes to extrapolation to off-label uses, according to a new study.
A recent study comparing usage of the infliximab biosimilar Inflectra (infliximab-dyyb; CT-P13) with that of the originator biologic (Remicade) among Medicare beneficiaries found that use of the biosimilar is increasing even though it accounted for less than 10% of total monthly administrations.
Study data also suggest some beneficiaries are switching from the reference product to the biosimilar. However, analyses by indication and prescribing clinician suggest that patients and physicians may still have concerns about extrapolation to gastrointestinal indications, according to the authors.
